| Summary: | 碩士 === 東海大學 === 管理碩士在職專班 === 95 === Biotechnology, the new、most developing industry in the world in the 21st century, one of the “Two-Trillion, Twin-Star” project and national-level development industry in Taiwan. Because of the importance and proactive, this study has evaluated efficient-structure and market-power base on biotechnology pharmaceutical companies from 1995 to 2005. The five profit-structure, including the rate of returns of assets (ROA), rate of returns of stockholder's equity (ROE), after tax net profit (RAT) , earning per share (EPS) and business net income (NSR), will be extended for the policy of industry development. The major conclusions of the empirical research are as following: (1) The average of operating technological efficiency, technological efficiency, and scale efficiency are 0.45、0628 and 0.725, that mean manager should improve those inefficiency branches (54.1%) through the enhancement of the management capability and the adjustment operational scale. (2)On the profit-structure, we can observe profit increasing by the improvement of operating technological efficiency, technological efficiency, and scale efficiency. Those results answer the efficient-structure hypothesis. Besides, we also observe profit increasing by concentration of the industry concentration and marketing share of individual company. (3)According to above, biotechnology pharmaceutical industry indeed has development potentical. How to improve competitivness? The strategy should be amplifing scale efficiency inside and augmenting marketing share outside.
|
|---|
